Literature DB >> 10087006

Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

S N Iyer1, G Gurujeyalakshmi, S N Giri.   

Abstract

A time course study was carried out to elucidate the mechanisms for antifibrotic effect of pirfenidone (PD). Hamsters were intratracheally (i.t.) instilled with saline (SA) or bleomycin (BL) (7.5 units/kg/5 ml). The animals were fed a diet containing 0.5% PD or the same control diet (CD) without the drug 2 days before and throughout the study. The animals were sacrificed at various times after instillation. The lung hydroxyproline level in BL + CD groups was gradually increased and peaked at 21 days to 181% of the SA + CD control. The BL + PD-treated groups showed a gradual decrease in their lung collagen content, showing a maximum reduction of 40% at day 21. The lung malondialdehyde levels of the BL + CD groups were increased by several-fold of the corresponding SA + CD groups at various times. The lung prolyl hydroxylase (PH) activities in the BL + CD groups were also increased by several-fold of the corresponding SA + CD groups at these time points. The hamsters in the BL + PD showed a gradual decrease in the lung malondialdehyde levels from 10 to 21days compared with their corresponding BL + CD groups. Treatment with PD also reduced the lung PH activities in the BL + PD groups compared with the corresponding BL + CD groups. However, PD failed to manifest any direct inhibitory effect on PH activity in vitro. BL treatment increased the lung procollagen I and III gene expressions in the BL + CD groups by several-fold at varying times compared with the corresponding SA + CD, and treatment with PD in the BL + PD groups significantly down-regulated the BL-induced overexpression of these genes. Studies evaluating the regulation of these genes at the transcriptional level revealed PD significantly reduced the transcription of PC I at 14 days. Our results indicate that the antifibrotic effect of PD was partly due to suppression of the BL-induced inflammatory events and partly due to down-regulation of BL-induced overexpression of lung procollagen I and III genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087006

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  51 in total

1.  Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis.

Authors:  Kevin O'Brien; James Troendle; Bernadette R Gochuico; Thomas C Markello; Jose Salas; Hilda Cardona; Jianhua Yao; Isa Bernardini; Richard Hess; William A Gahl
Journal:  Mol Genet Metab       Date:  2011-03-21       Impact factor: 4.797

Review 2.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

3.  Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.

Authors:  Avinandan Saha; Preyas J Vaidya; Vinod B Chavhan; Amolkumar Achlerkar; Jörg D Leuppi; Prashant N Chhajed
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia.

Authors:  Xuyou Zhu; Xia Fang; Wei Chen; Fei Han; Ziling Huang; Benfang Luo; Pan Gu; Long Zhang; Weizhe Qiu; Yu Zeng; Weiwei Rui; Xianghua Yi
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Combined Effects of Drugs and Plasticizers on the Properties of Drug Delivery Films.

Authors:  Cheryl L Jennings; Thomas D Dziubla; David A Puleo
Journal:  J Bioact Compat Polym       Date:  2016-06-21       Impact factor: 1.756

Review 6.  Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review.

Authors:  Nadim Srour; Bernard Thébaud
Journal:  Stem Cells Transl Med       Date:  2015-10-22       Impact factor: 6.940

Review 7.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

Review 8.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

9.  The multifaceted role of pirfenidone and its novel targets.

Authors:  José Macías-Barragán; Ana Sandoval-Rodríguez; Jose Navarro-Partida; Juan Armendáriz-Borunda
Journal:  Fibrogenesis Tissue Repair       Date:  2010-09-01

10.  Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.

Authors:  Huijuan Xiao; Xiaoxi Huang; Shiyao Wang; Zheng Liu; Run Dong; Dingyun Song; Huaping Dai
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.